Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 5/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776210 | 0.92 | BRAF (0.42) | IMPDH2BRAFCREBBPBRD4LIMK2 | |
| SCHEMBL16776401 | 0.90 | BRAF (0.42) | IMPDH2BRAFCREBBPBRD4LIMK2 | |
| SCHEMBL16775995 | 0.90 | BRAF (0.41) | BRAFLIMK2CNR1RPS6KA3RPS6KA2 | |
| SCHEMBL16775875 | 0.89 | RHOA (0.46) | BRAFCREBBPBRD4LIMK2RHOA | |
| SCHEMBL16776108 | 0.85 | CREBBP (0.45) | IMPDH2BRAFCREBBPBRD4LIMK2 | |
| SCHEMBL16776146 | 0.83 | HTR2C (0.48) | ALDH1A1 | |
| SCHEMBL16776424 | 0.82 | DYRK1A (0.40) | BRAF | |
| SCHEMBL16776144 | 0.82 | KMT2A (0.44) | CREBBPCNR1CA9RPS6KA2ALDH1A1 | |
| SCHEMBL16776011 | 0.82 | CA9 (0.38) | CNR1RPS6KA3CA9RPS6KA2ALDH1A1 | |
| SCHEMBL16776298 | 0.80 | RHOA (0.39) | BRAFRHOACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | IMPDH2 1200/4885BRAF 3419/4885CREBBP 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.